Vestmark Advisory Solutions Inc. Grows Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Vestmark Advisory Solutions Inc. increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 14.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 30,586 shares of the company’s stock after buying an additional 3,826 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Elanco Animal Health were worth $370,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Elanco Animal Health during the fourth quarter worth approximately $10,561,000. Arizona State Retirement System increased its stake in Elanco Animal Health by 0.8% in the fourth quarter. Arizona State Retirement System now owns 143,462 shares of the company’s stock valued at $1,737,000 after purchasing an additional 1,166 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in Elanco Animal Health in the fourth quarter valued at approximately $405,000. Atria Investments Inc increased its stake in Elanco Animal Health by 3.8% in the fourth quarter. Atria Investments Inc now owns 58,782 shares of the company’s stock valued at $712,000 after purchasing an additional 2,169 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in Elanco Animal Health by 11.0% in the fourth quarter. Victory Capital Management Inc. now owns 113,630 shares of the company’s stock valued at $1,376,000 after purchasing an additional 11,216 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

ELAN stock opened at $11.12 on Friday. The company has a market capitalization of $5.50 billion, a P/E ratio of 27.80, a PEG ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a twelve month low of $10.20 and a twelve month high of $18.80. The business has a 50 day simple moving average of $11.62 and a 200-day simple moving average of $12.90. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s revenue was down 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.08 earnings per share. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analysts Set New Price Targets

ELAN has been the topic of several recent analyst reports. Barclays dropped their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Piper Sandler dropped their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday. Morgan Stanley dropped their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. Finally, UBS Group dropped their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.